Janux Therapeutics, Inc. JANX
12.39 USD +0.35 (+2.91%)
At closeNov 12, 2026, 5:43 AM EST
12.39 0.00 0.00%
Pre-market · Nov 12, 5:43 AM ET
11.98 Day range 12.77
11.59 52-week range 35.34
- YTD
- -10.22%
- 1 year
- -57.08%
News
seekingalpha.com Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Janux Therapeutics Reports Initial Phase 1 JANX011 Data, Providing Clinical Validation For ARM Platform In Autoimmune Diseases A single 3 mg subcutaneous dose produced greater than 90% peripheral B-cell depletion in most participants, including two participants with B cells below the limit of detection, with B-cell…
businesswire.com Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial…
benzinga.com Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27 Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.
benzinga.com Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40 Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.
benzinga.com Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15 Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.
zacks.com Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.- benzinga.com Janux Therapeutics Q3 EPS $(0.34) Beats $(0.46) Estimate, Sales $9.290M Beat $7.746M Estimate Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 12.82 percent increase over losses of…
businesswire.com Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial…